Curated News
By: NewsRamp Editorial Staff
December 11, 2025
Sigyn's CardioDialysis Aims to Transform Heart Disease Treatment Using Dialysis Tech
TLDR
- Sigyn Therapeutics' CardioDialysis offers a competitive edge by potentially achieving 75-95% MACE reduction using existing dialysis infrastructure, surpassing current drug limitations.
- CardioDialysis works by deploying broad-spectrum blood purification on existing dialysis machines to clear inflammatory molecules and lipoproteins, with clinical trials planned in dialysis clinic settings.
- This therapy could significantly extend lives by reducing cardiovascular deaths, particularly benefiting ESRD patients who face 20 times higher cardiovascular disease incidence.
- CardioDialysis transforms kidney dialysis clinics into cardiovascular treatment centers, potentially adding $2.8 billion monthly to dialysis industry revenues by extending patient lives.
Impact - Why it Matters
This development matters because cardiovascular disease remains the world's leading cause of death, and current treatments have significant limitations. Statin drugs, while widely used, only reduce major cardiovascular events by about 25%, leaving substantial room for improvement. The dialysis patient population represents a particularly vulnerable group where cardiovascular mortality is exceptionally high and existing medications have shown limited effectiveness. By leveraging existing dialysis infrastructure that's already widely available, CardioDialysis could potentially bring advanced blood purification therapy to millions of patients who currently lack access to specialized apheresis centers. If successful, this technology could not only extend and improve lives but also create a new treatment paradigm where cardiovascular care becomes integrated with existing renal care systems, potentially making advanced therapy more accessible and affordable for broader populations.
Summary
Sigyn Therapeutics, a medical technology company developing dialysis-like therapies, has unveiled groundbreaking details about its CardioDialysis™ device, which aims to revolutionize cardiovascular disease treatment. Led by inventor CEO Jim Joyce, the company highlights that this first-in-industry medical device leverages existing dialysis infrastructure at over 7,500 U.S. clinics to perform blood purification, targeting a broad spectrum of inflammatory molecules and cholesterol-transporting lipoproteins. Unlike traditional statin drugs that achieve 25% reductions in Major Adverse Cardiovascular Events (MACE), Sigyn cites American Heart Association research showing lipoprotein apheresis (a similar blood purification method) achieves 75-95% MACE reductions, positioning CardioDialysis as a potentially superior alternative.
The company's strategy focuses initially on end-stage renal disease (ESRD) patients, where cardiovascular disease causes 67% of deaths and current drugs have proven ineffective. With 550,000 ESRD patients undergoing approximately 85 million dialysis treatments annually in the U.S., Sigyn sees an immediate clinical opportunity to administer CardioDialysis during regular dialysis sessions. The device has demonstrated clearance of twelve therapeutic targets in invitro studies and shown safety in animal trials at the University of Michigan. Sigyn's clinical approach is particularly innovative as it plans to conduct studies in dialysis clinics rather than hospital ICUs, significantly reducing time and costs while enrolling patients during their routine treatments.
Beyond ESRD patients, CardioDialysis represents a transformative opportunity for the dialysis industry, potentially converting kidney dialysis clinics into combined renal and cardiovascular treatment centers. The company estimates that extending ESRD patient lives could increase dialysis industry revenues by $2.8 billion monthly based on average per-patient revenues. Sigyn's broader pipeline includes ImmunePrep™ for cancer immunotherapy, ChemoPrep™ for targeted chemotherapy delivery, and ChemoPure™ for reducing chemotherapy toxicity. The company invites further engagement through its website at www.SigynTherapeutics.com and direct contact with CEO Jim Joyce.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sigyn's CardioDialysis Aims to Transform Heart Disease Treatment Using Dialysis Tech
